Myricetin and naringenin inhibit human squamous cell carcinoma proliferation and migration in vitro

Nutrition and Cancer

Volumn 66, Issue 7, 2014, Pages 1257-1267

  Maggioni, Daniele ^a   Nicolini, Gabriella ^a   Rigolio, Roberta ^a   Biffi, Luisa ^a   Pignataro, Lorenzo ^b   Gaini, Renato ^a   Garavello, Werner ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN D1; CYCLIN E; MYRICETIN; NARINGENIN; ANTINEOPLASTIC AGENT; CCNB1 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; FLAVANONE DERIVATIVE; FLAVONOID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL INVASION; CELL INVASION ASSAY; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; MOUTH SQUAMOUS CELL CARCINOMA; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA CELL LINE; WESTERN BLOTTING; WOUND HEALING; CELL CYCLE; CELL MOTION; DRUG EFFECTS; GENETICS; METABOLISM; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN B1; CYCLIN D1; FLAVANONES; FLAVONOIDS; HUMANS; MOUTH NEOPLASMS; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84908211500     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.951732     Document Type: Article

References (34)

1. Siegel R., Naishadham D., and Jemal A.: Cancer statistics. CA Cancer J Clin 62, 10-29, 2012
2. Warnakulasuriya S.: Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncology 46, 407-410, 2010.
3. Noguti J., De Moura CF., De Jesus GP., Da Silva VH., Hossaka TA, et al.: Metastasis from oral cancer: an overview. Cancer Genomics Proteomics, 9, 329-335, 2012.
4. Mascolo M., Siano M., Ilardi G., Russo D., Merolla F, et al.: Epigenetic disregulation in oral cancer. Int J Mol Sci 13, 2331-2353, 2012.
5. Garavello W., Lucenteforte E., Bosetti C., and La Vecchia C.: The role of foods and nutrients on oral and pharyngeal cancer risk. Minerva Stomatol 58, 25-34, 2009.
6. Shiboski CH., Schmidt BL., and Jordan RC.: Tongue and tonsilar carcinoma: increasing trends in the US population ages 20-44 years. Cancer 103, 1843-1849, 2005.
7. Romagnolo DF. and Selmin OI.: Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr 31, 206-238, 2012.
8. Benavente-García O. and Castillo J.: Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 56, 6185-6205, 2008.
9. Clere N., Faure S., Martinez MC., and Andriantsitohaina R.: Anticancer properties of flavonoids: roles in various stages of carcinogenesis. Cardiovasc Hematol Agents Med Chem 9 (2), 62-77, 2011.
10. Kanno S., Tomizawa A., Ohtake T., Koiwai K., Ujibe M, et al.: Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells. Toxicol Lett 166, 131-139, 2006.
11. Kanadaswami C., Lung-Ta Lee., Ping-Ping H Lee., Jiuan-Jiuan Hwang., Ferng-chun KE, et al.: The antitumor activities of flavonoids. In Vivo 19, 895-910, 2005.
12. Sabarinathan D., Mahalakshmi P., and Vanisree AJ.: Naringenin promote apoptosis in cerebrally implanted C6 glioma cells. Mol Cell Biochem 345, 215-222, 2010.
13. Park JH., Jin CY., Lee BK., Kim GY., Choi YH, et al.: Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells. Food Chem Toxicol 46, 3684-3690, 2008.
14. Kang NJ., Jung SK., Lee KW., and Lee HJ.: Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis. Ann N Y Acad Sci 1229, 124-132, 2011.
15. Ong KC. and Khoo HE.: Biological effects of myricetin. Gen Pharmacol 29, 121-126, 1997.
16. Gordon MH. and Roedig-Penman A.: Antioxidant activity of quercetin and myricetin in liposomes. Chem Phys Lipids 97, 79-85, 1998.
17. Miller EG., Peacock JJ., Bourland TC., Taylor SE., Wright JM., et al.: Inhibition of oral carcinogenesis by citrus flavonoids. Nutr Cancer 60, 69-74, 2008.
18. Tímár J., Csuka O., Remenár E., Répássy G., and Kásler M.: Progression of head and neck squamous cell cancer. Cancer Metastasis Review 24, 107-127, 2005.
19. Komissarova EV. and Rossman TG.: Arsenite induced poly(ADP-ribosyl)ation of tumor suppressor P53 in human skin keratinocytes as a possible mechanism for carcinogenesis associated with arsenic exposure. Toxicol Appl Pharmacol 243, 399-404, 2010.
20. Zhang Q., Zhao XH., and Wang ZJ.: Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE-510) by induction of G2/M arrest and apoptosis. Toxicol In Vitro 23, 797-807, 2009.
21. Morales P. and Haza AI.: Selective apoptotic effects of piceatannol and myricetin in human cancer cells. J Appl Toxicol 32, 986-993, 2012.
22. Kim W., Yang HJ., Youn H., Yun YJ., Seong KM, et al.: Myricetin inhibits Akt survival signaling and induces Bad-mediated apoptosis in a low dose ultraviolet (UV)-B-irradiated HaCaT human immortalized keratinocytes. J Radiat Res 51, 285-296, 2010.
23. Jin CY., Park C., Lee JH., Chung KT., Kwon TK, et al.: Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells. Toxicol In Vitro 23, 259-265, 2009.
24. Kanno S., Tomizawa A., Hiura T., Osanai Y., Shouji A, et al.: Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull 28, 527-530, 2005.
25. Jin CY., Park C., Lee JH., Chung KT., Kwon TK, et al.: Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells. Toxicol In Vitro 23, 259-265, 2009.
26. Phillips PA., Sangwan V., Borja-Cacho D., Dudeja V., Vickers SM, et al.: Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett 308, 181-188, 2011.
27. Hsiao YC., Hsieh YS., Kuo WH., Chiou HL., Yang SF, et al.: The tumor-growth inhibitory activity of flavanone and 2-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs. J Biomed Sci 14, 107-119, 2007.
28. Strobel P., Allard C., Perez-Acle T., Calderon R., Aldunate R, et al.: Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem J 386, 471-478, 2005.
29. Lee EJ., Kim DI., Kim WJ., and Moon SK.: Naringin inhibits matrix metalloproteinase-9 expression and AKT phosphorylation in tumor necrosis factor-alpha-induced vascular smooth muscle cells. Mol Nutr Food Res 53, 1582-1591, 2009.
30. Kim DI., Lee SJ., Lee SB., Park K., Kim WJ, et al.: Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis 29, 1701-1709, 2008.
31. Zhang Q., Zhao XH., and Wang ZJ.: Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE-510) by induction of G2/M arrest and apoptosis. Toxicol In Vitro 23, 797-807, 2009.
32. Kumamoto T., Fujii M., and Hou DX.: AKT is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem 332, 33-41, 2009.
33. Shih YW., Wu PF., Lee YC., Shi MD., and Chiang TA.: Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway. J Agric Food Chem 57, 3490-3499, 2009.
34. Lou C., Zhang F., Yang M., Zhao J., Zeng W, et al.: Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One 7 (12), e50956, 2012.